Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mohamed S. Hasim"'
Autor:
Mohamed S. Hasim, Carolyn Nessim, Patrick J. Villeneuve, Barbara C. Vanderhyden, Jim Dimitroulakos
Publikováno v:
Translational Oncology, Vol 11, Iss 4, Pp 988-998 (2018)
Anthracyclines, such as doxorubicin, are used as first-line chemotherapeutics, usually in combination therapies, for the treatment of advanced breast cancer. While these drugs have been successful therapeutic options, their use is limited due to seri
Externí odkaz:
https://doaj.org/article/dddf536142274f1496f3345080bca3a7
Autor:
Jair Bar, Mohamed S. Hasim, Tabassom Baghai, Nima Niknejad, Theodore J. Perkins, David J. Stewart, Harmanjatinder S. Sekhon, Patrick J. Villeneuve, Jim Dimitroulakos
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 525-535 (2016)
Non–small cell lung carcinoma (NSCLC) is the most common cause of cancer deaths, with platin-based combination chemotherapy the most efficacious therapies. Gains in overall survival are modest, highlighting the need for novel therapeutic approaches
Externí odkaz:
https://doaj.org/article/62c40392758141428b661fe1a30fdc89
Autor:
Mohamed S. Hasim, Marie Marotel, Jonathan J. Hodgins, Elisabetta Vulpis, Olivia J. Makinson, Sara Asif, Han-Yun Shih, Amit K. Scheer, Olivia MacMillan, Felipe G. Alonso, Kelly P. Burke, David P. Cook, Rui Li, Maria Teresa Petrucci, Angela Santoni, Padraic G. Fallon, Arlene H. Sharpe, Giuseppe Sciumè, André Veillette, Alessandra Zingoni, Douglas A. Gray, Arleigh McCurdy, Michele Ardolino
Trogocytosis modulates immune responses, with still unclear underlying molecular mechanisms. Using leukemia mouse models, we found that lymphocytes perform trogocytosis at high rates with tumor cells. While performing trogocytosis, both Natural Kille
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e2730a496530c215b2016d185c70d05
http://hdl.handle.net/11573/1633234
http://hdl.handle.net/11573/1633234
Autor:
Michele Ardolino, Giovanna Peruzzi, Silvano Sozzani, Seung-Hwan Lee, Han-Yu Shih, Gianluca Scarno, Giovanni Bernardini, Eleonora Russo, Laura Vian, Mattia Laffranchi, Angela Santoni, Luana Tomaipitinca, Angela Gismondi, Julija Mazej, Lena Müller, Chiara Di Censo, Marie Marotel, Yohei Mikami, Mohamed S. Hasim, Massimo Gadina, Giuseppe Sciumè, Andreas Diefenbach, Giuseppe Pietropaolo, Michael Bonelli, Cristina Capuano, Helena Stabile, Irene Mattiola, Sara Asif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a992aca4798c87016be9457099253cd
https://doi.org/10.1002/eji.202149209/v2/response1
https://doi.org/10.1002/eji.202149209/v2/response1
Publikováno v:
Cytokinegrowth factor reviews. 56
Oncolytic viruses (OVs) are immunotherapeutics capable of directly killing cancer cells and with potent immunostimulatory properties. OVs exert their antitumor effect, at least partially, by activating the antitumor immune response, of which NK cells
Autor:
Jim Dimitroulakos, Patrick James Villeneuve, Harmanjatinder S. Sekhon, Theodore J. Perkins, Mohamed S. Hasim, David J. Stewart, Tabassom Baghai, Nima Niknejad, Jair Bar
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 525-535 (2016)
Non–small cell lung carcinoma (NSCLC) is the most common cause of cancer deaths, with platin-based combination chemotherapy the most efficacious therapies. Gains in overall survival are modest, highlighting the need for novel therapeutic approaches
Autor:
Alexander E. G. Baker, Roger Y. Tam, Chandarong Choey, William L. Stanford, Laura Smith, Mohamed S. Hasim, Jim Dimitroulakos, Molly S. Shoichet, Julien Yockell-Lelièvre, Lisa M. Julian
Publikováno v:
Advanced materials (Deerfield Beach, Fla.). 31(7)
Cell behavior is highly dependent upon microenvironment. Thus, to identify drugs targeting metastatic cancer, screens need to be performed in tissue mimetic substrates that allow cell invasion and matrix remodeling. A novel biomimetic 3D hydrogel pla
Autor:
Carolyn Nessim, Mohamed S. Hasim, Patrick James Villeneuve, Barbara C. Vanderhyden, Jim Dimitroulakos
Publikováno v:
Translational Oncology
Translational Oncology, Vol 11, Iss 4, Pp 988-998 (2018)
Translational Oncology, Vol 11, Iss 4, Pp 988-998 (2018)
Anthracyclines, such as doxorubicin, are used as first-line chemotherapeutics, usually in combination therapies, for the treatment of advanced breast cancer. While these drugs have been successful therapeutic options, their use is limited due to seri
Autor:
Grant A Howe, Bin Xiao, Huijun Zhao, Khalid N Al-Zahrani, Mohamed S Hasim, James Villeneuve, Harmanjatinder S Sekhon, Glenwood D Goss, Luc A Sabourin, Jim Dimitroulakos, Christina L Addison
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)
Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TK
Externí odkaz:
https://doaj.org/article/21805c1dece148209f371f94cca74a0d